An expert at ESMO 2026 explains how liquid biopsy and ESR1 testing can help guide treatment for people with HR-positive metastatic breast cancer.
|Articles|July 10, 2015
Kara Maxwell Provides Advice for a Patient With Early Stage Breast Cancer
Author(s)Kara Maxwell
Kara Maxwell, instructor, medical oncologist, Basser Research Center for BRCA, University of Pennsylvania, provides advice for a patient with early stage breast cancer.
Advertisement
Kara Maxwell, instructor, medical oncologist, Basser Research Center for BRCA, University of Pennsylvania, provides advice for a patient with early stage breast cancer.
Advertisement
Related to this article
After breast cancer at 30, Aisha shares her journey through motherhood, a double mastectomy, body image struggles and the challenges of survivorship.
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.
Longer follow-up presented at the 2026 ESMO Congress showed that four already-approved treatments for early breast cancer, kidney cancer, colorectal cancer and stomach and esophageal cancer kept helping patients years later.
Dr. Jacqueline Barrientos shares how a targeted therapy, a determined care team and a stranger’s generosity gave a 72-year-old man with hairy cell leukemia and kidney failure a second chance.
Two phase 3 trials at ESMO 2026 brought new options for advanced endometrial cancer, and final results for Verzenio after another CDK4/6 drug showed a survival difference that was not statistically significant.
Dr. Robert Kreitman explains how CD22-targeted CAR T could help heavily pretreated patients.
Advertisement
Advertisement
Trending on CURE
1
Top 5 Takeaways From ESMO 2026 That Patients Should Know
2
3 Quality-of-Life Results From ESMO 2026 Patients Should Know
3
4 Long-Term Survival Results From ESMO 2026 Patients Should Know
4
What New KRAS Drug Data From ESMO 2026 Mean for Patients
5